HRP20120793T1 - Kristalni oblici nilotinib hci - Google Patents
Kristalni oblici nilotinib hci Download PDFInfo
- Publication number
- HRP20120793T1 HRP20120793T1 HRP20120793AT HRP20120793T HRP20120793T1 HR P20120793 T1 HRP20120793 T1 HR P20120793T1 HR P20120793A T HRP20120793A T HR P20120793AT HR P20120793 T HRP20120793 T HR P20120793T HR P20120793 T1 HRP20120793 T1 HR P20120793T1
- Authority
- HR
- Croatia
- Prior art keywords
- theta
- degrees
- nilotinib hcl
- ppm
- chemical shift
- Prior art date
Links
- 239000005536 L01XE08 - Nilotinib Substances 0.000 title 1
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 title 1
- 229960001346 nilotinib Drugs 0.000 title 1
- VTGGYCCJUPYZSX-UHFFFAOYSA-N 4-methyl-n-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide;hydrochloride Chemical compound Cl.C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 VTGGYCCJUPYZSX-UHFFFAOYSA-N 0.000 claims 16
- 239000000126 substance Substances 0.000 claims 10
- 238000000634 powder X-ray diffraction Methods 0.000 claims 8
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 claims 3
- 239000007787 solid Substances 0.000 claims 3
- 230000001747 exhibiting effect Effects 0.000 claims 2
- 238000004922 13C solid-state nuclear magnetic resonance spectroscopy Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 238000001228 spectrum Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Exhaust Gas Treatment By Means Of Catalyst (AREA)
Claims (12)
1. Kristalni Nilotinib HCl, naznačen time da su podaci odabrani iz skupine koja sadrži: uzorak rendgenske difrakcije praha koji ima vrške kod 5.7, 9.8, 15.0, 15.8 i 17.3 stupnjeva dva theta ± 0.2 stupnjeva dva theta; 13C NMR spektar čvrstog stanja sa signalima kod 113.1, 133.1, 160.9 ± 0.2 ppm; 13C NMR spektar čvrstog stanja koji ima razlike kemijskih pomaka između signala koji iskazuje najniži kemijski pomak i drugog u rasponu kemijskog pomaka od 100 do 180 ppm od 9.2, 29.2 i 57.0 ± 0.1 ppm, pri čemu signal koji iskazuje najniži kemijski pomak u području kemijskog pomaka od 100 do 180 ppm je na 103.9 ± 1 ppm; te njihove kombinacije.
2. Kristalni Nilotinib HCl prema zahtjevu 1, naznačen time da uzorak rendgenske difrakcije praha ima vrške kod 5.7, 9.8, 15.0, 15.8 i 17.3 stupnjeva dva theta ± 0.2 stupnjeva dva theta.
3. Kristalni Nilotinib HCl prema zahtjevu 1, naznačen time da ima 13C NMR spektar čvrstog stanja sa signalima kod 113.1, 133.1, 160.9 ±0.2 ppm.
4. Kristalni Nilotinib HCl prema zahtjevu 1, naznačen time da 13C NMR spektar čvrstog stanja ima razlike kemijskih pomaka između signala koji iskazuje najniži kemijski pomak i drugog u rasponu kemijskog pomaka od 100 do 180 ppm od 9.2, 29.2 i 57.0 ±0.1 ppm, pri čemu signal koji iskazuje najniži kemijski pomak u području kemijskog pomaka od 100 do 180 ppm je na 103.9 ± 1 ppm.
5. Kristalni Nilotinib HCl prema zahtjevu 2, dodatno naznačen time da uzorak rendgenske difrakcije praha ima vrške kod 7.5, 11.4, 18.6, 19.6 i 20.7 stupnjeva dva theta ± 0.2 stupnjeva dva theta.
6. Kristalni Nilotinib HCl prema zahtjevu 2, dodatno naznačen time da uzorak rendgenske difrakcije praha ima vrške kod 7.6, 11.4, 18.7, 19.7 i 20.7 stupnjeva dva theta ± 0.2 stupnjeva dva theta.
7. Kristalni Nilotinib HCl prema zahtjevu 1, naznačen time da kristalni oblik je bezvodan.
8. Kristalni Nilotinib HCl prema zahtjevu 1, koji ima manje od 10% tež/tež. Nilotinib HCl oblika A, pri čemu oblik A je naznačen time da uzorak rendgenske difrakcije praha ima barem jedan maksimum odabran od 8.5, 11.0, 11.5, 17.2, 18.8, 19.2, 20.8, 22.1 i 26.0 stupnjeva dva theta ±0.2 stupnjeva dva theta.
9. Kristalni Nilotinib HCl prema zahtjevu 8, koji ima manje od 10% tež/tež. Nilotinib HCl oblika A, pri čemu oblik A je naznačen time da uzorak rendgenske difrakcije praha ima barem dva maksimuma odabrana od 8.5, 11.0, 11.5, 17.2, 18.8, 19.2, 20.8, 22.1 i 26.0 stupnjeva dva theta ±0.2 stupnjeva dva theta.
10. Kristalni Nilotinib HCl prema zahtjevu 8, koji ima manje od 10% tež/tež. Nilotinib HCl oblika A, pri čemu oblik A je naznačen time da uzorak rendgenske difrakcije praha ima barem četiri maksimuma odabrana od 8.5, 11.0, 11.5, 17.2, 18.8, 19.2, 20.8, 22.1 i 26.0 stupnjeva dva theta ±0.2 stupnjeva dva theta.
11. Kristalni Nilotinib HCl prema zahtjevu 8, koji ima manje od 10% tež/tež. Nilotinib HCl oblika A, pri čemu oblik A je naznačen time da uzorak rendgenske difrakcije praha ima sve maksimume odabrane od 8.5, 11.0, 11.5, 17.2, 18.8, 19.2, 20.8, 22.1 i 26.0 stupnjeva dva theta ± 0.2 stupnjeva dva theta.
12. Farmaceutski pripravak naznačen time da sadrži kristalni oblik Nilotinib HCl kako je definirano u bilo kojem od zahtjeva 1-8 u kombinaciji sa barem jednom farmaceutski prihvatljivom pomoćnom tvari.
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11156108P | 2008-11-05 | 2008-11-05 | |
| US15578909P | 2009-02-26 | 2009-02-26 | |
| US17745409P | 2009-05-12 | 2009-05-12 | |
| US22721009P | 2009-07-21 | 2009-07-21 | |
| US24070909P | 2009-09-09 | 2009-09-09 | |
| US24251409P | 2009-09-15 | 2009-09-15 | |
| US24679909P | 2009-09-29 | 2009-09-29 | |
| US24937609P | 2009-10-07 | 2009-10-07 | |
| PCT/US2009/063365 WO2010054056A2 (en) | 2008-11-05 | 2009-11-05 | Nilotinib hci crystalline forms |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20120793T1 true HRP20120793T1 (hr) | 2012-12-31 |
Family
ID=41666779
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20120793AT HRP20120793T1 (hr) | 2008-11-05 | 2012-10-03 | Kristalni oblici nilotinib hci |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US8227477B2 (hr) |
| EP (2) | EP2262793B1 (hr) |
| JP (1) | JP5486012B2 (hr) |
| KR (2) | KR101251726B1 (hr) |
| CN (1) | CN102203084B (hr) |
| CA (1) | CA2740794A1 (hr) |
| DK (1) | DK2262793T3 (hr) |
| ES (1) | ES2394258T3 (hr) |
| HR (1) | HRP20120793T1 (hr) |
| PL (1) | PL2262793T3 (hr) |
| TW (1) | TW201022240A (hr) |
| WO (1) | WO2010054056A2 (hr) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN2010KO00035A (hr) * | 2010-01-15 | 2016-09-02 | ||
| US20110263701A1 (en) * | 2010-04-21 | 2011-10-27 | Sigal Blau | Gabapentin enacarbil compositions |
| CN103038227A (zh) * | 2010-06-21 | 2013-04-10 | 特瓦制药工业有限公司 | 尼洛替尼盐及其晶形 |
| EP2966072A3 (en) | 2010-06-21 | 2016-02-24 | Teva Pharmaceutical Industries, Ltd. | Crystalline forms of nilotinib hydrobromide, succinate, glutamate, acetate, l-malate and maleate |
| CN102453024B (zh) * | 2010-10-27 | 2014-09-03 | 浙江九洲药业股份有限公司 | 一种尼罗替尼盐酸盐晶型及其制备方法 |
| EP2648519A4 (en) * | 2010-11-26 | 2014-04-30 | Hetero Research Foundation | NEW POLYMORPH OF NILOTINIB HYDROCHLORIDE |
| IN2011CH01887A (hr) * | 2011-06-02 | 2012-12-14 | ||
| AR086913A1 (es) * | 2011-06-14 | 2014-01-29 | Novartis Ag | 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas |
| ES2564969T3 (es) * | 2012-02-09 | 2016-03-30 | Natco Pharma Limited | Proceso para la preparación de clorhidrato de nilotinib |
| US9061028B2 (en) | 2012-02-15 | 2015-06-23 | Natco Pharma Limited | Process for the preparation of Nilotinib |
| AU2013332205B2 (en) * | 2012-10-15 | 2017-08-31 | Apotex Inc. | Solid forms of Nilotinib hydrochloride |
| US9567317B2 (en) | 2012-10-19 | 2017-02-14 | Basf Se | Multicomponent crystalline system comprising nilotinib and selected co-crystal formers |
| AU2014259029B2 (en) * | 2013-04-24 | 2018-08-16 | Dr. Reddys Laboratories Limited | Polymorphic forms of nilotinib hydrochloride |
| US9636340B2 (en) | 2013-11-12 | 2017-05-02 | Ayyappan K. Rajasekaran | Kinase inhibitors |
| WO2015092624A1 (en) | 2013-12-16 | 2015-06-25 | Ranbaxy Laboratories Limited | Nilotinib mono-oxalate and its crystalline form |
| WO2016020891A1 (en) | 2014-08-08 | 2016-02-11 | Dr. Reddy’S Laboratories Limited | Process for the preparation of polymorphic forms of nilotinib |
| US10016423B2 (en) | 2014-10-16 | 2018-07-10 | Apotex Inc. | Solid forms of nilotinib hydrochloride |
| CN106478603B (zh) * | 2015-08-25 | 2021-01-01 | 江苏豪森药业集团有限公司 | 尼洛替尼盐酸盐的新晶型及其制备方法和医药用途 |
| EA036204B1 (ru) * | 2015-10-16 | 2020-10-14 | Нобел Илач Санайи Ве Тиджарет А.Ш. | Фармацевтические композиции нилотиниба гидрохлорида |
| WO2017129694A1 (en) | 2016-01-26 | 2017-08-03 | Farma Grs, D.O.O. | Nilotinib dinitrate (v) and crystalline forms thereof |
| PT3430004T (pt) | 2016-03-14 | 2020-08-21 | Pliva Hrvatska D O O | Formas em estado sólido de sais de nilotinib |
| EP3404025B1 (en) * | 2017-05-16 | 2019-12-04 | F.I.S.- Fabbrica Italiana Sintetici S.p.A. | Process for the preparation of pure nilotinib and its salt |
| CZ2017821A3 (cs) | 2017-12-20 | 2019-07-03 | Zentiva, K.S. | Léková forma obsahující krystalický nilotinib |
| CN113321647A (zh) * | 2018-06-15 | 2021-08-31 | 汉达癌症医药责任有限公司 | 激酶抑制剂的盐类及其组合物 |
| EP3877379A4 (en) * | 2018-11-05 | 2022-08-31 | Laurus Labs Limited | CRYSTALLINE FORM OF NILOTINIB HYDROCHLORIDE, METHOD FOR PREPARING IT AND PHARMACEUTICAL COMPOSITION CONTAINING IT |
| AU2022292092A1 (en) | 2021-06-19 | 2024-02-01 | Helm Ag | Granulate composition comprising nilotinib |
| EP4122452A1 (en) | 2021-07-23 | 2023-01-25 | KRKA, d.d., Novo mesto | Pharmaceutical composition comprising nilotinib and method of manufacturing the same |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
| GB0325031D0 (en) | 2003-10-27 | 2003-12-03 | Novartis Ag | Organic compounds |
| SA06270147B1 (ar) | 2005-06-09 | 2009-12-22 | نوفارتيس ايه جي | عملية لتخليق 5-(مثيل–1h–إيميدازول–1-يل )–3-(ثلاثي فلـورو مثيل)–بنزامـين |
| MY146795A (en) | 2005-06-09 | 2012-09-28 | Novartis Ag | Process for the synthesis of organic compounds |
| GT200600315A (es) * | 2005-07-20 | 2007-03-19 | Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida | |
| GT200600316A (es) * | 2005-07-20 | 2007-04-02 | Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida. | |
| CN101228150B (zh) * | 2005-07-20 | 2014-10-15 | 诺华股份有限公司 | 4-甲基-n-[3-(4-甲基-咪唑-1-基)-5-三氟甲基-苯基]-3-(4-吡啶-3-基-嘧啶-2-基氨基)-苯甲酰胺的晶形 |
| KR100674813B1 (ko) | 2005-08-05 | 2007-01-29 | 일양약품주식회사 | Ｎ-페닐-2-피리미딘-아민 유도체 및 그의 제조방법 |
| FR2889524B1 (fr) | 2005-08-05 | 2008-08-29 | Rhodia Chimie Sas | Procede de formation d'une liaison carbone-azote |
| US20100016590A1 (en) * | 2008-07-17 | 2010-01-21 | Teva Pharmaceutical Industries Ltd. | Nilotinib intermediates and preparation thereof |
-
2009
- 2009-11-05 EP EP09752057A patent/EP2262793B1/en not_active Revoked
- 2009-11-05 CN CN200980144606.XA patent/CN102203084B/zh active Active
- 2009-11-05 CA CA2740794A patent/CA2740794A1/en not_active Abandoned
- 2009-11-05 DK DK09752057.1T patent/DK2262793T3/da active
- 2009-11-05 US US12/612,943 patent/US8227477B2/en active Active
- 2009-11-05 JP JP2011534915A patent/JP5486012B2/ja active Active
- 2009-11-05 ES ES09752057T patent/ES2394258T3/es active Active
- 2009-11-05 KR KR1020107014884A patent/KR101251726B1/ko active IP Right Grant
- 2009-11-05 PL PL09752057T patent/PL2262793T3/pl unknown
- 2009-11-05 KR KR1020127021115A patent/KR20120111743A/ko not_active Application Discontinuation
- 2009-11-05 WO PCT/US2009/063365 patent/WO2010054056A2/en active Application Filing
- 2009-11-05 EP EP12182091.4A patent/EP2530081A3/en not_active Withdrawn
- 2009-11-05 TW TW098137645A patent/TW201022240A/zh unknown
-
2012
- 2012-06-27 US US13/535,105 patent/US8592442B2/en active Active
- 2012-10-03 HR HRP20120793AT patent/HRP20120793T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW201022240A (en) | 2010-06-16 |
| PL2262793T3 (pl) | 2013-01-31 |
| EP2530081A2 (en) | 2012-12-05 |
| JP2012508178A (ja) | 2012-04-05 |
| CN102203084B (zh) | 2014-10-29 |
| ES2394258T3 (es) | 2013-01-30 |
| CA2740794A1 (en) | 2010-05-14 |
| KR101251726B1 (ko) | 2013-04-05 |
| JP5486012B2 (ja) | 2014-05-07 |
| EP2262793A2 (en) | 2010-12-22 |
| CN102203084A (zh) | 2011-09-28 |
| US20130096304A1 (en) | 2013-04-18 |
| WO2010054056A2 (en) | 2010-05-14 |
| WO2010054056A3 (en) | 2010-09-16 |
| KR20100099257A (ko) | 2010-09-10 |
| EP2262793B1 (en) | 2012-10-03 |
| KR20120111743A (ko) | 2012-10-10 |
| US8227477B2 (en) | 2012-07-24 |
| US8592442B2 (en) | 2013-11-26 |
| EP2530081A3 (en) | 2013-04-10 |
| US20100190812A1 (en) | 2010-07-29 |
| DK2262793T3 (da) | 2012-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20120793T1 (hr) | Kristalni oblici nilotinib hci | |
| HRP20151324T1 (hr) | Soli nilotiniba i njihovi kristalni oblici | |
| HRP20121028T1 (hr) | Kristalni oblici febuksostata | |
| CR8247A (es) | FORMA CRISTALINA BETA-d DEL CLORHIDRATO DE IVABRADINA, SU PROCEDIMIENTO DE PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LA CONTIENEN | |
| HRP20171175T1 (hr) | Novi triciklički spojevi | |
| CR8248A (es) | Forma cristalina beta del clorhidrato de ivabradina, su procedimiento de preparacion y composiciones farmaceuticas que la contienen | |
| ES2524380T3 (es) | Sales de raltegravir y formas cristalinas de las mismas | |
| HRP20160654T1 (hr) | 1-(3,3-DIMETILBUTIL)-3-(2-FLUOR-4-METIL-5-(7-METIL-2-(METILAMINO)PIRIDO[2,3-d]PIRIMIDIN-6-IL)FENIL)UREA KAO INHIBITOR Raf KINAZE U LIJEČENJU RAKA | |
| HRP20150356T1 (hr) | Kristalni oblici soli prasugrela | |
| ECSP066914A (es) | FORMA CRISTALINA dd DEL CLORHIDRATO DE LA IVABRADINA, SU PROCEDIMIENTO DE PREPARACIÓN Y LAS COMPOSICIONES FARMACÉUTICAS QUE LA CONTIENEN | |
| RS54742B1 (sr) | Kristalni oblik (r)-7-hlor-n-(hinuklidin-3-il)benzo[b]tiofen-2-karboksamid hidrohlorid monohidrata | |
| JP2015506941A5 (hr) | ||
| WO2008081041A3 (en) | Amorphous and crystalline forms of rivastigmine hydrogentartrate | |
| ES2492673T3 (es) | Formas cristalinas de un ingrediente farmacéutico activo | |
| HRP20160363T1 (hr) | Soli desfesoterodina | |
| WO2007092574A3 (en) | Crystalline forms of ciclesonide | |
| FR2946638B1 (fr) | Nouveau procede de preparation de nanoparticules cristallines a partir d'une vitroceramique | |
| TH92419S (th) | ไฟสัญญาณสำหรับยานพาหนะ | |
| TH84705B (th) | เครื่องบันทึกการรับจ่ายเงิน | |
| TH110757B (th) | อุปกรณ์สำหรับการเชื่อมต่อ | |
| TH86594B (th) | กล่องสำหรับอุปกรณ์อิเล็กทรอนิค | |
| TH114769S (th) | ผ้าอนามัย | |
| TH114309S (th) | ผ้าอนามัย | |
| TH114307S (th) | ผ้าอนามัย | |
| TH114306S (th) | ผ้าอนามัย |